Yuji Uehara

Targeting the FGF/FGFR axis and its co-alteration allies

Yuji Uehara, Sadakatsu Ikeda, K.H. Kim et al. · ESMO Open · 2022 · 25 citations · Full text

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy

Yuji Uehara, Taiki Hakozaki, Rui Kitadai et al. · Translational Lung Cancer Research · 2022 · 21 citations · Full text

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced <scp>NSCLC</scp> with <scp><i>KRAS</i></scp>, <scp><i>MET</i></scp>, <scp><i>FGFR</i></scp>, <scp><i>RET</i></scp>, <scp><i>BRAF</i></scp>, and <scp><i>HER2</i></scp> alterations

Yuji Uehara, Kageaki Watanabe, Taiki Hakozaki et al. · Thoracic Cancer · 2022 · 21 citations · Full text

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital

Yuji Uehara, Takafumi Koyama, Yuki Katsuya et al. · JAMA Network Open · 2023 · 17 citations · Full text

Molecular changes associated with the development of resistance to imatinib in an imatinib‐sensitive canine neoplastic mast cell line carrying a <i><scp>KIT</scp></i> c.1523A&gt;T mutation

Masato Kobayashi, Shiori Kuroki, Yu Tanaka et al. · European Journal Of Haematology · 2015 · 14 citations

Imatinib-resistant Sublines, Mast Cell Disorder, Immunology +21